Background. Neoadjuvant radiotherapy (RT) is increasingly advocated for the management of soft tissue sarcoma (STS). Therefore, this study sought to characterize the impact of neoadjuvant RT on rates of R0 resection and overall survival (OS) in extremity STS patients undergoing surgery. Methods. From January 2003 to December 2012, the study identified patients with a diagnosis of extremity STS from the National Cancer Database. After exclusion of patients younger than 18 years, not treated by surgery, who had metastases at diagnosis, intraoperative RT, and missing or unknown data, 27,969 patients were identified. Logistic regression and Cox-proportional hazard analysis were used to compare rates of R0 resection among preoperative, postoperative, and no-RT cohorts and to determine predictors of R0 resection and OS. Results. The mean age of the patients was 59.5 ± 17.1 years, and 45.9% were female. The median tumor size was 10.5 cm. The data showed that 51% of the patients did not receive RT, 11.8% received preoperative RT, and 37.2% received postoperative RT. The rates of R0 resection were 90.1% for the preoperative RT cohort, 74.9% for the postoperative RT cohort, and 79.9% for the no-RT cohort (P \ 0.001). The independent predictors for achievement of R0 resection included academic facility type (odds ratio 1 The evolution of the treatment for extremity STS has led to the widespread use of limb-sparing surgery as the cornerstone of treatment with curative intent, and radiotherapy (RT) is frequently used as a key component of these combined-method approaches.
Soft tissue sarcomas (STS) are rare tumors of mesenchymal origin, affecting approximately 12,000 patients per year in the United States. 1 The evolution of the treatment for extremity STS has led to the widespread use of limb-sparing surgery as the cornerstone of treatment with curative intent, and radiotherapy (RT) is frequently used as a key component of these combined-method approaches. [2] [3] [4] [5] Important prospective studies, including randomized trials, have demonstrated the impact of adjuvant and neoadjuvant RT on increased local control and decreased local recurrence of extremity STS, although these studies have not demonstrated an overall survival (OS) benefit with the addition of RT to surgery. [6] [7] [8] [9] [10] [11] Retrospective studies from large databases have suggested that adjuvant RT may improve OS for patients with high-grade STS, although the mechanism for this association remains undefined. [12] [13] [14] [15] The timing and dose of RT in combination with surgery have been thoroughly studied in the prospective, randomized SR2 trial completed by the National Cancer Institute of Canada. 16 Importantly, although the timing of RT with respect to acute and chronic morbidities of treatment differed significantly, the oncologic outcome did not differ between the pre-and postoperative RT groups. Overall, the rate of acute postsurgical complications was higher in the preoperative RT group, whereas the rate of long-term complications such as fibrosis, edema, and joint stiffness was higher in the postoperative RT group. 16 Yet, local recurrence or OS did not differ significantly. 17 After this study, formal recommendations for the timing of RT with respect to surgery became a patient-specific decision made by multidisciplinary teams at experienced sarcoma centers weighing the risks and benefits. 18 Since the SR2 trial, neoadjuvant RT has gained increasing acceptance in the multimodality management of primary extremity STS. 4 Proponents of preoperative RT maintain that the acute morbidities of RT tend to be reversible, whereas the chronic morbidities tend to be irreversible. 19 Radiation oncologists endorse the smaller treatment fields as well as the well-defined tumor volume. [19] [20] [21] In very select situations with specific radiosensitive histologic subtypes, typically myxoid liposarcoma, preoperative RT can cause appreciable tumor necrosis as measured by the Response Evaluation Criteria in Solid Tumors. [22] [23] [24] Finally, the ability to achieve negative surgical margins after preoperative RT is often cited as a reason to favor neoadjuvant RT, although data in support of this contention are limited.
The creation of the National Cancer Database (NCDB) has allowed researchers to examine the outcomes of rare tumors, such as extremity STS, on a larger scale. Moreover, by providing data on key variables such as surgical margin status and timing of RT, investigators are able to examine hypotheses, which was not previously possible with other large data sets.
In this study, we sought to analyze the relationship between preoperative RT and surgical margin status in a large hospital-based data set, specifically hypothesizing that neoadjuvant RT leads to a higher incidence of R0 resection. We also sought to examine the impact of preoperative RT and surgical margin status on OS for both low-and high-grade patients.
METHODS
Using the NCDB, we retrospectively identified 72,457 patients who had a diagnosis of STS of the extremity according to the International Classification of Diseases for Oncology, 3rd revision, between 1 January 2003 and 31 December 2012. Patients younger than 18 years, who did not undergo surgery, who had stage 4 disease at diagnosis, and who had unknown surgical margin status, tumor grade, tumor size, or vital status were excluded from the study. Patients who received a combination of pre-and postoperative RT, intraoperative RT, or unknown delivery of RT also were excluded. Overall, 27,969 patients were included in the final analysis.
Frequency tables were generated for the 14,263 patients in the no-RT group, 3309 patients in the preoperative RT group, and 10,397 patients in the postoperative RT group (Table 1 ). The variables examined were age, sex, race, year of diagnosis, facility type, Charlson-Deyo score, grade, histology, tumor size, surgical margins, receipt of chemotherapy, and chemotherapy-surgery sequence. As shown in Table 1 , histologies were grouped into 22 separate subtypes including a grouping for sarcoma not otherwise specified (NOS). Year of diagnosis and tumor size were grouped into categories for summary statistics. Summary statistics were reported as mean ± standard deviation or median (range) where appropriate.
We performed standard univariate descriptive analyses. Multivariate logistic regression was performed to evaluate preoperative RT as a predictor of R0 resection. Other predictors selected in our model were age, sex, race, facility type, year of diagnosis, histology, grade, tumor size, Charlson-Deyo score, radiation-surgery sequence, and systemic-surgery sequence. Tumor size and year of diagnosis were treated as continuous variables. Histologic subtypes were identical to those described in Table 1 .
A Cox-proportional hazard analysis and corresponding Kaplan-Meier curve were generated to evaluate OS, measured as time to last contact or death, in months. Disease-specific survival is not captured in the NCDB data set. To evaluate the impact that sequencing of RT on OS has on patients for whom RT typically is routinely indicated, we also performed a subgroup Cox-proportional hazard analysis for patients with grade 3 or 4 histology, comprising a total of 16,511 patients.
All statistical analyses were performed using Stata version 14 (StataCorp LP, College Station, TX, USA). Significance was set at a P value lower than 0.05. All patient information was de-identified and therefore exempt from the University of California, Davis Institutional Review Board approval.
RESULTS
The clinicopathologic characteristics of the patient cohorts are depicted in Table 1 . The mean ages for the cohorts were 59.7, 58.9, and 59.6 years, respectively, and the majority in each cohort was male. The majority of the patients also were Caucasian, and sarcoma NOS was the most prevalent histologic subtype in each group. Of the patients who received preoperative RT, 73.4% had either grade 3 or 4 histology. Of the patients who received postoperative RT, 69.4% had grade 3 or 4 histology. The patients not receiving RT were more evenly distributed, with 51.5% having grade 1 or 2 histology. The patients receiving preoperative RT also tended to have larger tumors, with 46.8% of patients having tumors larger than 10 cm, compared with 31.6% in the no-RT group and 27.7% in the postoperative RT group (P \ 0.001).
Of the patients who received preoperative RT, 90.1% had a subsequent R0 resection compared with 79.9% of the patients who did not receive RT and 75% of the patients who received postoperative RT (P \ 0.001). Overall, postoperative RT was associated with a 2.5 times greater rate of an R1 or R2 resection (25%) than preoperative RT (9.6%; P \ 0.0001).
The results of multivariable logistic regression for predictors of R0 resection are depicted in Table 2 . Preoperative RT was associated with a significantly greater likelihood of obtaining an R0 resection, with an odds ratio (OR) of 1.826 (95% confidence interval [CI] 1.608-2.073; P \ 0.0001) compared with an OR of 0.674 (95% CI 0.632-0.720; P \ 0.0001) for postoperative RT, using no RT as the reference. An R0 resection also was more likely to be achieved at an academic/research center (OR 1.366; 95% CI, 1.204-1.55; P \ 0.0001). As shown in Table 2 , no other variables were associated with achieving an R0 resection, including receipt of preoperative chemotherapy.
In contrast, several histologic subtypes, including liposarcomas and malignant peripheral nerve sheath tumors, were associated with a lower likelihood of an R0 resection (Table 2) . Interestingly, grade 2 tumors were associated with a lower likelihood of an R0 resection (OR 0.878; 95% CI 0.788-0.978; P = 0.018), as was increasing tumor size (OR 0.999 per mm increase in tumor size; 95% CI 0.999-0.999; P \ 0.0001). A Charlson-Deyo score of 1 also was negatively associated with an R0 resection (compared with a score of 0), although a score of 2 or greater was not.
As depicted in Table 3 , Cox-proportional hazard analysis demonstrated that both pre-and postoperative RT were associated with increased OS. With a hazard ratio (HR) of 0.80 (95% CI 0.78-0.82; P \ 0.0001), postoperative RT was associated with a greater likelihood of survival than preoperative RT (HR 0.94; 95% CI 0.91-0.98; P \ 0.001).
As shown in Fig. 1 , we did observe statistically significant differences in OS between R0 resection and both R1 (HR 1.13; 95% CI 1.08-1.19; P \ 0.0001) and R2 (HR 1.221; 95% CI 1.15-1.30; P \ 0.001) resection. We then performed a subgroup Cox-proportional hazard analysis limited to patients with grade 3 or 4 histology because these patients are more likely to receive RT routinely as a component of their STS treatment (Table 4) . Overall, our results remained consistent, as shown by the hazard ratios for preoperative RT and OS (0.89; 95% CI 0.85-0.94; P \ 0.001) and postoperative RT (0.76; 95% CI 0.74-0.79; P \ 0.001). We also observed a survival benefit with R0 resection compared with R1 and R2 resections.
DISCUSSION
Using the NCDB, we analyzed the impact of neoadjuvant RT on surgical margins in the largest STS patient cohort to date, to our knowledge. We observed that preoperative RT was significantly associated with an increased likelihood for negative surgical margins, thereby providing evidence for the underlying hypothesis that preoperative RT allows for sterilization of the surgical margins and increases the likelihood of achieving an oncologically optimal resection. Similar to prior studies, we also observed that R0 resection was associated with superior OS. 25, 26 Additionally, we observed a survival benefit with both neoadjuvant and adjuvant RT.
The principal findings of the Canadian NCI SR2 trial showed no difference in progression-free survival or local recurrence between the pre-and postoperative RT arms of the study. It did show a benefit with preoperative RT for OS during 3 years. 16 However, the Canadian NCI SR2 trial was not powered to detect differences in this secondary end point. Interestingly, in this seminal trial, the rate of margin negativity was comparable between the pre-and postoperative RT groups (83% vs. 85%). Therefore, despite the comparable OS between the pre-and postoperative RT groups in our hospital-based analysis, the statistically significant greater rate of R1 and R2 resections in the postoperative RT cohort is a key finding. Although several studies did not observe margin status to be an independent predictor of survival in STS (likely due to the importance of other biologic drivers of outcome such as tumor grade, tumor size, and tumor histology), [27] [28] [29] [30] R0 resection has other benefits, such as the potential effects on function and morbidity from additional operations and higher RT doses after R1/R2 resection, which should also be considered. 25, 26, [31] [32] [33] [34] [35] In addition, an R0 resection can be difficult to achieve depending on tumor size and location, and our data seem to support the tendency for clinicians to endorse preoperative RT in those cases given the greater use of preoperative RT for tumors with a larger size and higher rates of grade 3 and 4 histology. However, although neoadjuvant RT can cause tumor necrosis, it is uncommon for it to achieve significant tumor shrinkage or downstaging, and typically, the extent of the surgical procedure is not altered by preoperative OR odds ratio, CI confidence interval, NOS not otherwise specified RT. 4, [19] [20] [21] [22] [23] [24] Yet, preoperative RT has been shown in animal models to thicken the pseudocapsule through hyalinization, thus theoretically reducing the potential for disruption and histologically positive margins. 36 As multi-modality treatment recommendations for STS continue to evolve, treatment must be individualized for the patient, and there is wide institutional variation based on local specialty expertise and experience. [2] [3] [4] [5] However, when treatment options for STS patients are considered, it is important to acknowledge factors influencing outcome that are tumor specific and treatment related. Two of the tumorspecific factors that merit attention are histologic grade and histologic subtype. We observed that the survival benefit of negative surgical margins was increased for high-grade sarcoma patients. Although studies, including the landmark National Cancer Institute of Canada (NCIC) trial, have historically shown no impact of RT timing on survival, 16, 30, 37, 38 retrospective analyses have shown a survival benefit in favor of preoperative RT. 39 These results may represent the impact of facility type where STS care was HR hazard ratio, CI confidence interval, NOS not otherwise specified rendered, a confounding factor that also may explain our results.
In fact, key studies by Yang et al. 7 and Beane et al. 8 in a randomized setting found no difference in survival when RT was added to limb-sparing surgery for patients with extremity STS. Consequently, one explanation of our hospital-based registry data is that they are biased by confounding factors inherent in retrospective analyses, such as selection bias. However, it also is important to acknowledge that the results of randomized trials may poorly generalize to the population at large because fewer than 5% of patients in the United States participate in randomized trials. These randomized studies also carry a risk of type 2 error. Although we are not able to resolve these critical questions, we emphasize that our data are concordant with prior retrospective studies showing an association between receipt of RT and improved STS survival (which some authors have attributed to higher compliance with guideline-based care).
When the findings of this study are evaluated, its limitations must be considered. The NCDB does not contain information on local recurrence, a significant topic when the impact of RT on overall oncologic outcome is considered. The effectiveness of RT in decreasing rates of local recurrence has been clearly documented. 7, 8, 25, 40 A recent study by Willeumier et al. 41 demonstrated the superiority of neoadjuvant RT over adjuvant RT in improving local control. However, due to limitations of the NCDB database, the relationship of margin status to local recurrence cannot be corroborated in our data. Information on local recurrence rates would clearly strengthen this analysis, particularly given the statistically significant differences in rates of R0, R1, and R2 resections among the preoperative, postoperative, and no-RT cohorts.
Additionally, retrospective studies are at risk for sources of bias. In this study, both pre-and postoperative RT were associated with a survival benefit compared with surgery alone, although the magnitude of the favorable effect was greater for postoperative RT. One explanation for these findings is that the preoperative RT patients appeared to have an imbalance in baseline prognostic factors (tumor size and high grade), which biased these patients to have a worse survival. We attempted to reduce this bias by analyzing only the grades 3 and 4 patients, but these associations remained consistent. Given that the findings of O'Sullivan et al. 16 showed no difference in key survival end points between pre-and postoperative RT for extremity STS, the differences in OS we observed between the pre-and postoperative RT cohorts may have been an artifact of the retrospective nature of our analysis. Ultimately, this important question requires further analysis with more rigorous statistical matching techniques to control for key prognostic factors.
In summary, our analysis of a large NCDB cohort of extremity STS patients showed that preoperative RT is associated with a significantly higher incidence of R0 resection, and that both neoadjuvant and adjuvant RT are associated with improved survival. Therefore, we consider these data to be further evidence showing the benefits of preoperative RT. However, we recognize that the sequencing of RT remains a key component of individualized multi-modality STS care, and this is best provided in the context of an experienced STS referral center. HR hazard ratio, CI confidence interval, NOS not otherwise specified
